The company attaches great importance to research and development. Currently, the professional and technical talents engaged in technology R&D account for nearly 20% of the company's total number of employees, of which technical personnel with a bachelor's degree or above account for more than 60%. There are several R&D personnel with PhDs and senior professional titles, with annual R&D expenses accounting for more than 3% of sales revenue. The company provides superior salary packages and benefits for R&D personnel, and raises the actual salary income of talents through an annual salary system, high-performance appraisal, year-end business award incentives and other measures.
The company's R&D center has a reasonable layout, covering an area of more than 3,000 m2, and is equipped with complete instruments and equipment such as small-scale synthesis, pilot scale-up, trial production and product testing, which supports the promotion and industrialization of new products and technologies. The research equipment of the R&D center is at the leading level in China, with advanced synthesis and detection equipment such as HPLC, GC, IC, ICP-MS, LC-MS, which is a strong support for drug research and development.
In terms of international innovation cooperation, the company has cooperated with companies such as Sandoz Pharmaceuticals (Austria) and MIP company (Germany). With the deepening of commercial cooperation, the R&D center has also continuously learned from the innovative R&D experience of large foreign pharmaceutical companies and carried out technical cooperation on some cutting-edge topics. The company vigorously promotes the construction of innovation mechanisms integrating enterprises, universities, research institutes, and end-users in China, and has signed school-enterprise cooperation agreements with Guangdong University of Technology, Guangdong Pharmaceutical University, Guangdong Food and Drug Vocational College, and Heyuan Vocational and Technical College to jointly create a collaborative innovation platform for the new pharmaceutical industry in Heyuan, provide public services in the professional field, promote technology in pharmaceutical testing and research and development, jointly cultivate talents, and promote the development of the industry and the transformation of achievements.
The company has strong technical strength and has successively established the Guangdong Engineering Technology R&D Center, Provincial Enterprise Technology Center, Guangdong Doctoral Workstation, and Heyuan Cephalosporin API Enterprise Key Laboratory. The company has always adhered to the concept of independent innovation and technology first, and promoted the construction of intellectual property rights. By the end of 2023, it had obtained 14 authorized invention patents, 41 utility model patents and 25 software copyrights.
The company's R&D center actively carried out technical cooperation and exchanges with powerful pharmaceutical R&D institutions and manufacturers at home and abroad, and successively developed cephalosporins, including Cefuroxime Sodium and Cefuroxime Axetil, covering the first to fifth generations, to assist the company in obtaining production approval, so that the company can maintain its advantages and leading position in industrial structure and production technology.
The R&D Center undertakes the project declaration and qualification identification of the company, and assists the company to obtain corresponding honorary qualifications.
Over the years, the company has been recognized as a "National High-tech Enterprise", "National Intellectual Property Advantage Enterprise", "Guangdong Specialized Small and Medium-sized Enterprise", "Guangdong Innovative Enterprise", "Guangdong Excellent Enterprise in Pharmaceutical Industry" and "Benchmark Enterprise in Pharmaceutical Industry".
Service Hotline
TOP